Revlimid regimen improves survival in MM

Belgian non-profit patient support group the European Myeloma Platform says that data from multiple myeloma patients previously treated with Celegene's anticancer agent Revlimid (lenalidomide), in combination with the steroid dexamethasone, indicates that the regimen confers an average survival time of 35 months. The results, which are from two large randomized Phase III trials, were announced at the 11th International Myeloma Workshop in Kos, Greece.

Previously, it was reported that 98% of newly-diagnosed patients, under the age of 65, in a large randomized Phase III trial who received the Revlimid/dexamethasone combination were still alive at year one. In addition, 95% of study participants 65 years old and over were also alive after one year of treatment.